Martínez-Pérez Alejandra, Granda-Díaz Rocío, Aguilar-García Candelaria, Sordo-Bahamonde Christian, Gonzalez Segundo
Department of Functional Biology, Immunology, Universidad de Oviedo, Oviedo, Spain.
Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Spain.
Biomark Res. 2024 Oct 18;12(1):126. doi: 10.1186/s40364-024-00671-0.
Treatment based on immune checkpoint blockade has revolutionized cancer therapy. Despite the remarkable success achieved and the preclinical development of multiple checkpoint inhibitors targeting other checkpoints, only antibodies targeting the PD-1/PD-L1 axis and CTLA-4 have been approved for patient treatment, especially in solid tumors. Currently, with the approval of relatlimab, a LAG-3 blocking antibody, a third player, has been used in the fight against cancer. The endorsement of relatlimab marks a significant milestone in cancer immunotherapy, opening new avenues for combination therapies and enhancing treatment outcomes. However, the complex biology of LAG-3 may hinder its full development as a therapeutic alternative. In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment.
基于免疫检查点阻断的治疗彻底改变了癌症治疗方式。尽管已取得显著成功，并且针对其他检查点的多种检查点抑制剂也在临床前进行了研发，但目前仅有靶向PD-1/PD-L1轴和CTLA-4的抗体被批准用于患者治疗，尤其是在实体瘤治疗中。目前，随着LAG-3阻断抗体relatlimab的获批，第三种药物已被用于抗癌治疗。relatlimab的获批标志着癌症免疫治疗的一个重要里程碑，为联合治疗开辟了新途径，并改善了治疗效果。然而，LAG-3复杂的生物学特性可能会阻碍其作为一种治疗选择得到充分发展。在这篇综述中，我们深入探讨了LAG-3的生物学特性及其在癌症治疗中的现状和未来发展。
